116 related articles for article (PubMed ID: 15017321)
1. Of blood, bones, and broccoli: warfarin-vitamin K interactions.
Neafsey P
Home Healthc Nurse; 2004 Mar; 22(3):178-82; quiz 183-4. PubMed ID: 15017321
[No Abstract] [Full Text] [Related]
2. A case of intolerance to warfarin dosing in an intermediate metabolizer of CYP2C9.
Lee SY; Kim JS; Kim JW
Yonsei Med J; 2005 Dec; 46(6):843-6. PubMed ID: 16385662
[TBL] [Abstract][Full Text] [Related]
3. Genetic testing for warfarin dosing? Not yet ready for prime time.
Bussey HI; Wittkowsky AK; Hylek EM; Walker MB
Pharmacotherapy; 2008 Feb; 28(2):141-3. PubMed ID: 18225960
[No Abstract] [Full Text] [Related]
4. Seaweed, vitamin K, and warfarin.
Bartle WR; Madorin P; Ferland G
Am J Health Syst Pharm; 2001 Dec; 58(23):2300. PubMed ID: 11763808
[No Abstract] [Full Text] [Related]
5. Genetic help for a blood-thinner balancing act? There's little evidence yet that a genetic test improves the safety of warfarin.
Harv Heart Lett; 2007 Dec; 18(4):1-2. PubMed ID: 18219801
[No Abstract] [Full Text] [Related]
6. Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements.
Aquilante CL; Langaee TY; Lopez LM; Yarandi HN; Tromberg JS; Mohuczy D; Gaston KL; Waddell CD; Chirico MJ; Johnson JA
Clin Pharmacol Ther; 2006 Apr; 79(4):291-302. PubMed ID: 16580898
[TBL] [Abstract][Full Text] [Related]
7. Elevated international normalized ratio from vitamin K supplement discontinuation.
Miesner AR; Sullivan TS
Ann Pharmacother; 2011 Jan; 45(1):e2. PubMed ID: 21205949
[TBL] [Abstract][Full Text] [Related]
8. Polymorphisms in VKORC1 have more impact than CYP2C9 polymorphisms on early warfarin International Normalized Ratio control and bleeding rates.
Lund K; Gaffney D; Spooner R; Etherington AM; Tansey P; Tait RC
Br J Haematol; 2012 Jul; 158(2):256-261. PubMed ID: 22571356
[TBL] [Abstract][Full Text] [Related]
9. Should we be applying warfarin pharmacogenetics to clinical practice? No, not now.
Rosove MH; Grody WW
Ann Intern Med; 2009 Aug; 151(4):270-3, W95. PubMed ID: 19687493
[TBL] [Abstract][Full Text] [Related]
10. Optimal dosing of warfarin and other coumarin anticoagulants: the role of genetic polymorphisms.
Daly AK
Arch Toxicol; 2013 Mar; 87(3):407-20. PubMed ID: 23376975
[TBL] [Abstract][Full Text] [Related]
11. Genotype-guided dosing of warfarin.
Mega JL; Giugliano RP
Clin Chem; 2014 Jul; 60(7):920-2. PubMed ID: 24691686
[No Abstract] [Full Text] [Related]
12. Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients.
Miao L; Yang J; Huang C; Shen Z
Eur J Clin Pharmacol; 2007 Dec; 63(12):1135-41. PubMed ID: 17899045
[TBL] [Abstract][Full Text] [Related]
13. Warfarin resistance.
Sinxadi P; Blockman M
Cardiovasc J Afr; 2008; 19(4):215-7. PubMed ID: 18776969
[TBL] [Abstract][Full Text] [Related]
14. Delayed warfarin induced skin necrosis in a patient with poor warfarin metabolizing activity due to interrupted warfarin therapy.
Gaikwad T; Ghosh K; Shetty S
Eur J Clin Pharmacol; 2013 Feb; 69(2):293-4. PubMed ID: 22706625
[No Abstract] [Full Text] [Related]
15. Genetic and environmental risk factors for oral anticoagulant overdose.
Verstuyft C; Robert A; Morin S; Loriot MA; Flahault A; Beaune P; Funck-Brentano C; Jaillon P; Becquemont L
Eur J Clin Pharmacol; 2003 Mar; 58(11):739-45. PubMed ID: 12634980
[TBL] [Abstract][Full Text] [Related]
16. Severely diminished response to vitamin K-treatment for self-inflicted warfarin intoxication in a patient genotyped as CYP2C9*3*3.
Bäckström T; Barkman G; Lindh JD; Eliasson E
Eur J Clin Pharmacol; 2009 Oct; 65(10):1055. PubMed ID: 19484231
[No Abstract] [Full Text] [Related]
17. Evaluation of warfarin management with international normalized ratio self-testing and online remote monitoring and management plus low-dose vitamin k with genomic considerations: a pilot study.
Bussey HI; Bussey M; Bussey-Smith KL; Frei CR
Pharmacotherapy; 2013 Nov; 33(11):1136-46. PubMed ID: 24038412
[TBL] [Abstract][Full Text] [Related]
18. Communicating the safety essentials of oral anticoagulant therapy.
Lamarche K; Heale R
Home Healthc Nurse; 2007; 25(7):448-56; quiz 457-8. PubMed ID: 17667004
[No Abstract] [Full Text] [Related]
19. Monitoring warfarin therapy. How the INR keeps your patient safe.
Oertel LB
Nursing; 1999 Nov; 29(11):41-4; quiz 45. PubMed ID: 10633719
[No Abstract] [Full Text] [Related]
20. Dynamic pharmacogenetic models in anticoagulation therapy.
Bon Homme M; Reynolds KK; Valdes R; Linder MW
Clin Lab Med; 2008 Dec; 28(4):539-52. PubMed ID: 19059061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
